Two Sigma Advisers LP Purchases 103,500 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Two Sigma Advisers LP boosted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 452.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 126,400 shares of the company's stock after purchasing an additional 103,500 shares during the quarter. Two Sigma Advisers LP owned about 0.27% of 4D Molecular Therapeutics worth $704,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after buying an additional 92,791 shares in the last quarter. Millennium Management LLC increased its stake in 4D Molecular Therapeutics by 1,607.1% during the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after acquiring an additional 1,337,497 shares during the last quarter. JPMorgan Chase & Co. raised its position in 4D Molecular Therapeutics by 159.5% during the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock valued at $4,568,000 after purchasing an additional 504,086 shares during the period. Norges Bank bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $2,790,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of 4D Molecular Therapeutics by 2,084.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company's stock worth $2,500,000 after purchasing an additional 428,285 shares during the period. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Trading Up 2.0%

Shares of 4D Molecular Therapeutics stock traded up $0.08 during trading on Thursday, hitting $3.91. 102,579 shares of the stock traded hands, compared to its average volume of 826,847. The stock's fifty day simple moving average is $3.24 and its 200 day simple moving average is $4.71. The firm has a market cap of $180.90 million, a P/E ratio of -1.37 and a beta of 2.84. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). As a group, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. The Goldman Sachs Group decreased their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Royal Bank of Canada decreased their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, May 24th. Finally, Chardan Capital decreased their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.56.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.